Figure 3.

Tip60 depletion influences MEC sensitivity to cisplatin. (a) Immunoblot to detect γH2AX in COMMA cells expressing scr or siTip60 siRNAs and left untreated (ctr) or treated for 24 h with IR (10 Gy) or cisplatin (10 μM). Actin, loading control. (b) Quantitation of AnnexinV/7-AAD⁺ apoptotic cells in cultures of scr- or siTip60-expressing COMMA cells that were left untreated or treated for 24 h with the indicated doses of cisplatin. Ctr, vehicle control. Data are the mean±S.E.M. (n=3) and are representative of two trials. (c) Immunoblot to detect cleaved PARP in scr- or siTip60-expressing COMMA cells that were left untreated or treated for 24 h with 10 μM cisplatin as in (a). Results are representative of three trials. Vinculin, loading control. (d) Quantitation of apoptosis as in (b) of WAPcre;PTEN^f/f cells that were infected with shGFP- or shTip60-expressing lentivirus and treated for 24 h with the indicated doses of cisplatin. Data are the mean±S.E.M. (n=3) and are representative of two trials. (e) Quantitation of RT-PCR analysis of relative p21/Cdkn1a and Puma/Bbc3 mRNA levels in WAPcre;PTEN^f/f cells infected as in (c) and treated with 2 μM cisplatin for 24 h. Data were analyzed as in Figure 1d and are representative of two trials. *P<0.05 and ***P<0.001